Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

J Mark Gergen


  • Svp, Chief Operating Officer at Halozyme Therapeutics Inc (HALO), 2017-02-24
  • Executive Vp, Coo at Mirati Therapeutics Inc. (MRTX), 2016-01-26
  • Svp, Corporate Development at Amylin Pharmaceuticals Inc (AMLN), 2012-08-10
Insider Trading: Sales See All
Company Symbol Price Amount Relationship Remaining Holdings Date Form 4
MRTX $25.92 10,000 Officer 5,748 2016-01-15 Filing
AMLN $17.11 1,846 Officer, Other 53,814 2012-03-01 Filing
AMLN $17.03 7,518 Officer 54,826 2012-02-23 Filing